NoGeneST™ Anti-CCKBR Aptamer, aCCKBR aptamer-1 sodium

Name: NoGeneST™ Anti-CCKBR Aptamer, aCCKBR aptamer-1 sodium
SKU: NRYF-0625-HZ42
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ42]

A DNA aptamer that acts as a specific antagonist of the cholecystokinin B receptor (CCKBR).

Target:: CCKBR

Type:: DNA

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Description

This is an engineered DNA aptamer that binds with high specificity to the cholecystokinin B receptor (CCKBR). The aptamer functions as a pure antagonist, binding to the receptor without triggering the downstream signaling pathways normally activated by its natural ligands, gastrin and cholecystokinin. Its ability to block this pathway makes it a valuable tool for studying the role of CCKBR in gastrointestinal physiology and its involvement in cancer.

Type

DNA

Properties

Size

1 mg; 5 mg; 10 mg

Appearance

Supplied as a lyophilized white to off-white solid.

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

CCKBR

Full Name

Cholecystokinin B Receptor

Alternative Names

CCK2R; Gastrin receptor

Gene ID

887

Uniprot ID

P32239

Target Overview

The Cholecystokinin B Receptor (CCKBR) is a G protein-coupled receptor found predominantly in the central nervous system and the gastrointestinal tract. It is activated by the peptide hormones gastrin and cholecystokinin (CCK) and is involved in physiological processes such as gastric acid secretion, anxiety, and satiety. Importantly, CCKBR is frequently overexpressed in several malignancies, including gastric, colorectal, and pancreatic cancers, where its activation can promote tumor growth. This makes the receptor a significant target for oncology research and drug development.

Publications